Navigation Links
CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
Date:1/30/2008

PALO ALTO, Calif., Jan. 30 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that it will release fourth quarter and year end financial results for 2007 after the market closes on Tuesday, February 26, 2008. Company management will webcast a conference call at 5:00 p.m. EST, 2:00 p.m. PST, on the company's website.

To access the live webcast, please log on to the Company's website at http://www.cvt.com and go to the Investor Information section. Alternatively, domestic callers may participate in the conference call by dialing (866) 524-6247, and international callers may participate in the conference call by dialing (706) 679-3061. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Tuesday, March 4, 2008. Domestic callers can access the replay by dialing (800) 642-1687, and international callers can access the replay by dialing (706) 645-9291; the PIN access number is 32378484.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, i
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
2. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
3. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
5. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
6. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
7. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
8. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
9. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
10. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
11. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)DALLAS, Dec. 3 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a deb
(Date:12/3/2009)PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot
(Date:12/3/2009)WALTHAM, Mass., Dec. 3 Inverness Medical Innovations, Inc. (NYSE: IMA ), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and h
(Date:12/3/2009)NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D.,Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd.,( http://www.beikebiotech.com ), spoke at a conference on Hig
Breaking Biology Technology:Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 2Beike Biotechnology CSO Speaks on Role of Stem Cells in Treating Diabetic Foot Disease at IPA Diabetic Foot Care Conference, India 3
...new research field called transformation optics ma...cloak of invisibility and ultra-powerful microscop..."metamaterials." , The field, which applies mathe...theory of general relativity, will be described in...e journal Science . The article will appear in th...
...ceutical,Laboratories, Ltd. (Amex: CPD ) announce...its second quarter of fiscal year 2009, ended Sept...troit-based Caraco Pharmaceutical Laboratories, Lt... generic and private-label,pharmaceuticals to the ...re chains and managed care providers., Safe Harbo...
...nalytical Technologies,Inc. (AATI), based in Ames,...ding an additional 1200 ft2 of space to current op... space the company occupies in Building 4 on the,I...0 year old analytical,instrumentation company will...earch Park Campus, the expansion will make the com...
Other Biology Technology:New research field promises radical advances in optical technologies 2New research field promises radical advances in optical technologies 3New research field promises radical advances in optical technologies 4Caraco Pharmaceutical Laboratories Ltd. to Announce Second Quarter of Fiscal Year 2009 Results on October 23, 2008 2Advanced Analytical Technologies, Inc. Expands Into New Office and Production Space 2
(Date:12/3/2009)WALL, N.J., Dec. 3 BIO-key International, Inc. (OTC Bulletin Board: BKYI), a leader in wireless public safety and finger-based biometric identification solutions, announced that a majority of its sha
(Date:12/3/2009)A coating on windows or solar panels that repels grime and dirt? Expanded battery storage capacities for the next electric car? New Tel Aviv University research, just published in Nature Nanotechnolo
(Date:12/3/2009)Grand Rapids, Mich. (Dec. 3, 2009) Van Andel Research Institute (VARI) researchers have determined precisely how the plant hormone abscisic acid (ABA) works at the molecular level to help plants re
Breaking Biology News(10 mins):BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3A window that washes itself? 2VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Research team finds first evolutionary branching for bilateral animals 10060 1Research team finds first evolutionary branching for bilateral animals 10060 2Hand Washing Habits Still Need Improvement 3A Survey 58146 1NBCH Issues Guide to Help Employers Design Benefit Plans that Keep People Healthy 58141 1NBCH Issues Guide to Help Employers Design Benefit Plans that Keep People Healthy 58141 2NBCH Issues Guide to Help Employers Design Benefit Plans that Keep People Healthy 58141 3
...journal PLoS Biology has been assessed by Thomson ...s PLoS Biology among the most highly cited journal...tistic for a journal less than two years old, from...at supports open access to the scientific and medi...PLoS Biology above such established journals as EM...
...es matters after all. But for flying snakes, small...esearchers. , In the May 15, 2005, issue of the J...ed the effects of size and behavior of flying snak... gliders. , "Despite their lack of wing-like appen...," said lead scientist and author Jake Socha, Ph.D...
...cent of women rely on their healthcare providers t...rcent said their doctor has talked to them about c...virus (HPV) - according to a new survey released b...nals (ARHP). HPV is extremely common, affecting an... their lifetime, in some cases staying dormant unt...
Other Biology News:The first impact factor for PLoS Biology ?13.9 2Researchers reveal secrets of flying snakes 2Researchers reveal secrets of flying snakes 3Survey reveals women and doctors aren't talking about HPV 2Survey reveals women and doctors aren't talking about HPV 3
Custom Production Service - Purification from AbD Serotec
Single-stranded carrier DNA, 3 x 1 ml from Dualsystems Biotech AG
Rat Big Endothelin-1 (Big ET-1) EIA Kit from Assay Designs/Stressgen Bioreagents
Goat Anti-Qa-1 (L-12) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products: